{"title":"ELOVL3作为新的肝癌预后标志物的鉴定","authors":"Yiyang Chen, Wanbang Zhou, Yiju Gon, Xi Ou","doi":"10.5937/afmnai40-40853","DOIUrl":null,"url":null,"abstract":"Introduction. The incidence of liver cancer is increasing globally. Fatty acids in lipid metabolism are associated with cancer risk by maintaining cancer cell membrane structure and transducing cancer signaling, and their increased synthesis promotes tumor growth, angiogenesis, and tumor metastasis. Methods. After identification of the ELOVL3 gene involved in fatty acid metabolism, which is related to the prognosis of liver cancer, its expression level was extracted from The Cancer Genome Atlas (TCGA) database, and differential analysis, survival analysis, clinical correlation analysis and nomogram were used to predict the survival rate. A comprehensive meta-analysis was performed to further evaluate the prognostic value of ELOVL3. Finally, enrichment analysis and immune analysis were performed on the high and low expression groups of ELOVL3 gene to explore the value of ELOVL3 in predicting the prognosis and immunotherapy of liver cancer patients. Results. Patients with high ELOVL3 expression had poor overall survival and progression-free survival. The nomogram and the area under the ROC curve also indicated that the expression of ELOVL3 gene had high accuracy in predicting the survival time of liver cancer patients. The expression of ELOVL3 was significantly different in the early stage of tumor grade, tumor stage and T stage. Enrichment analysis and immunological analysis revealed a variety of information. The immunotherapy analysis also showed that low ELOVL3 was more effective than high ELOVL3 when receiving immunotherapy. Conclusion. The expression of ELOVL3 gene is significantly elevated in HCC and is associated with cancer development and poor prognosis.","PeriodicalId":7132,"journal":{"name":"Acta Facultatis Medicae Naissensis","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Identification of ELOVL3 as a novel prognostic marker for liver cancer\",\"authors\":\"Yiyang Chen, Wanbang Zhou, Yiju Gon, Xi Ou\",\"doi\":\"10.5937/afmnai40-40853\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction. The incidence of liver cancer is increasing globally. Fatty acids in lipid metabolism are associated with cancer risk by maintaining cancer cell membrane structure and transducing cancer signaling, and their increased synthesis promotes tumor growth, angiogenesis, and tumor metastasis. Methods. After identification of the ELOVL3 gene involved in fatty acid metabolism, which is related to the prognosis of liver cancer, its expression level was extracted from The Cancer Genome Atlas (TCGA) database, and differential analysis, survival analysis, clinical correlation analysis and nomogram were used to predict the survival rate. A comprehensive meta-analysis was performed to further evaluate the prognostic value of ELOVL3. Finally, enrichment analysis and immune analysis were performed on the high and low expression groups of ELOVL3 gene to explore the value of ELOVL3 in predicting the prognosis and immunotherapy of liver cancer patients. Results. Patients with high ELOVL3 expression had poor overall survival and progression-free survival. The nomogram and the area under the ROC curve also indicated that the expression of ELOVL3 gene had high accuracy in predicting the survival time of liver cancer patients. The expression of ELOVL3 was significantly different in the early stage of tumor grade, tumor stage and T stage. Enrichment analysis and immunological analysis revealed a variety of information. The immunotherapy analysis also showed that low ELOVL3 was more effective than high ELOVL3 when receiving immunotherapy. Conclusion. The expression of ELOVL3 gene is significantly elevated in HCC and is associated with cancer development and poor prognosis.\",\"PeriodicalId\":7132,\"journal\":{\"name\":\"Acta Facultatis Medicae Naissensis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Facultatis Medicae Naissensis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5937/afmnai40-40853\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Facultatis Medicae Naissensis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5937/afmnai40-40853","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0
摘要
介绍。肝癌的发病率在全球范围内呈上升趋势。脂质代谢中的脂肪酸通过维持肿瘤细胞膜结构和传导癌症信号与癌症风险相关,其合成增加促进肿瘤生长、血管生成和肿瘤转移。方法。在鉴定出与肝癌预后相关的参与脂肪酸代谢的ELOVL3基因后,从the cancer Genome Atlas (TCGA)数据库中提取其表达水平,采用差异分析、生存分析、临床相关分析和nomogram预测生存率。采用综合meta分析进一步评价ELOVL3的预后价值。最后对ELOVL3基因高表达组和低表达组进行富集分析和免疫分析,探讨ELOVL3基因在预测肝癌患者预后和免疫治疗中的价值。结果。ELOVL3高表达的患者总生存期和无进展生存期较差。nomogram和ROC曲线下面积也显示ELOVL3基因的表达对肝癌患者生存时间的预测具有较高的准确性。ELOVL3的表达在肿瘤分级、肿瘤分期和T期的早期有显著差异。富集分析和免疫学分析揭示了多种信息。免疫治疗分析也显示,在接受免疫治疗时,低ELOVL3比高ELOVL3更有效。结论。ELOVL3基因在HCC中的表达显著升高,与肿瘤发展和不良预后相关。
Identification of ELOVL3 as a novel prognostic marker for liver cancer
Introduction. The incidence of liver cancer is increasing globally. Fatty acids in lipid metabolism are associated with cancer risk by maintaining cancer cell membrane structure and transducing cancer signaling, and their increased synthesis promotes tumor growth, angiogenesis, and tumor metastasis. Methods. After identification of the ELOVL3 gene involved in fatty acid metabolism, which is related to the prognosis of liver cancer, its expression level was extracted from The Cancer Genome Atlas (TCGA) database, and differential analysis, survival analysis, clinical correlation analysis and nomogram were used to predict the survival rate. A comprehensive meta-analysis was performed to further evaluate the prognostic value of ELOVL3. Finally, enrichment analysis and immune analysis were performed on the high and low expression groups of ELOVL3 gene to explore the value of ELOVL3 in predicting the prognosis and immunotherapy of liver cancer patients. Results. Patients with high ELOVL3 expression had poor overall survival and progression-free survival. The nomogram and the area under the ROC curve also indicated that the expression of ELOVL3 gene had high accuracy in predicting the survival time of liver cancer patients. The expression of ELOVL3 was significantly different in the early stage of tumor grade, tumor stage and T stage. Enrichment analysis and immunological analysis revealed a variety of information. The immunotherapy analysis also showed that low ELOVL3 was more effective than high ELOVL3 when receiving immunotherapy. Conclusion. The expression of ELOVL3 gene is significantly elevated in HCC and is associated with cancer development and poor prognosis.